ENFUEGO THERAPEUTICS
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. The company was founded by Chad Pecot in 2019 and is headquartered in Pittsboro, North Carolina.
ENFUEGO THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-02-01
Address:
Pittsboro, North Carolina, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
615-305-3955
Current Employees Featured
Founder
More informations about "Enfuego Therapeutics"
Enfuego Therapeutics 2025 Company Profile: Valuation, Funding ...
Enfuego Therapeutics General Information Description. Operator of a biotech company intended to treat lung, pancreatic and colon cancers. The company is developing RNA interference …See details»
EnFuego Therapeutics - LinkedIn
EnFuego Therapeutics | 545 followers on LinkedIn. EnFuego Therapeutics is pioneering tumor-selective, mutant-specific RNAi molecules to solve cancer’s greatest challenges.See details»
Enfuego Therapeutics - Contacts, Employees, Board Members, …
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. ... Experience the new Crunchbase, …See details»
Enfuego Therapeutics Inc. - VentureRadar
Enfuego Therapeutics' novel RNA interference-(RNAi)-based and antisense oligo therapeutics are intended to treat cancer. We’re going after the big players in cancer, trying to develop drugs …See details»
Enfuego Therapeutics - Crunchbase
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. Search Crunchbase. Start Free Trial . …See details»
Enfuego Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Jan 23, 2025 Explore Enfuego Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Neoplasms, Technology Platform:siRNA, …See details»
Enfuego Therapeutics | CipherBio
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. See all funding and science results with …See details»
ENFUEGO THERAPEUTICS - Enfuego Therapeutics, Inc. Trademark …
Mark For: ENFUEGO THERAPEUTICS® trademark registration is intended to cover the categories of scientific and technological services, namely, scientific research, design, analysis …See details»
Enfuego Therapeutics, Inc. (Enfuego Therapeutics, Inc.) - 药物管线_ …
Oncogenic mutations in the KRAS gene are well-established drivers of cancer. While the recently developed KRAS G12C inhibitors offer a targeted KRAS therapy and have shown success in …See details»
Enfuego Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Enfuego Therapeutics Inc. of Pittsboro, NC. Get the latest business insights from Dun & Bradstreet.See details»
Enfuego Therapeutics Inc. | North Carolina Biotech Center
Enfuego Therapeutics Inc. Enfuego Therapeutics Inc. Enfuego Therapeutics is developing novel RNA interference-(RNAi)-based and antisense oligo therapeutics. Company Location. 5151 …See details»
Firm - SBIR
EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi)-based therapeutics. RNAi is particularly …See details»
Chad Pecot: EnFuego Therapeutics is making a new generation of …
Oct 6, 2024 Chad Pecot, CEO of EnFuego Therapeutics, shared on X: ”Coming out of ‘stealth mode’ today with my hair on fire. EnFuego Therapeutics is making a new generation of RNA …See details»
UNC Innovation & Entrepreneurship - Innovate Carolina
Mar 16, 2020 In launching EnFuego Therapeutics, Pecot used innovation and entrepreneurship resources available at Carolina to develop his startup journey, including KickStart Venture …See details»
RePORT 〉 RePORTER
Awardee Organization ENFUEGO THERAPEUTICS INC. Description. Abstract Text. Project Summary The proto-oncogene KRAS is one of the most critical genes in cancer, yet, as a drug …See details»
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
Itself to be widely regarded as “undruggable”. EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi) …See details»
Development of EFTX-001 to target KRAS mutations in cancer
Jun 1, 2020 We have established a C Corporation, EnFuego Therapeutics, Inc. to address the growing number of ?undruggable? targets in cancer by using RNA interference (RNAi)-based …See details»
Fired Up for RNA - UNC Research Stories
Jan 21, 2025 Pecot’s engineered RNA and proteins are fueling his startup company, EnFuego Therapeutics, which he founded in 2019. He hopes to spend the next year conducting safety …See details»
EFTX-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
EFTX-001, Initially developed by Enfuego Therapeutics, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms,Respiratory Diseases ...See details»
Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as …
23 hours ago EMERYVILLE, Calif., March 26, 2025--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization …See details»